Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Mei HuangHerbert Y Meltzer

Abstract

Atypical antipsychotic drugs, which are more potent direct acting antagonists of brain serotonin (5-HT)(2A) than dopamine (DA) D(2) receptors, preferentially enhance DA and acetylcholine (ACh) efflux in the rat medial prefrontal cortex (mPFC) and hippocampus (HIP), compared with the nucleus accumbens (NAc). These effects may contribute to their ability, albeit limited, to improve cognitive function and negative symptoms in patients with schizophrenia. Asenapine (ASE), a new multireceptor antagonist currently in development for the treatment of schizophrenia and bipolar disorder, has complex serotonergic properties based upon relatively high affinity for multiple serotonin (5-HT) receptors, particularly 5-HT(2A) and 5-HT(2C) receptors. In the current study, the effects of ASE on DA, norepinephrine (NE), 5-HT, ACh, glutamate, and gamma-aminobutyric acid (GABA) efflux in rat mPFC, HIP, and NAc were investigated with microdialysis in awake, freely moving rats. ASE at 0.05, 0.1, and 0.5 mg/kg (s.c.), but not 0.01 mg/kg, significantly increased DA efflux in the mPFC and HIP. Only the 0.5 mg/kg dose enhanced DA efflux in the NAc. ASE, at 0.1 and 0.5 mg/kg, significantly increased ACh efflux in the mPFC, but only the 0.5 mg/kg dose of ...Continue Reading

References

Mar 1, 1990·Pharmacology, Biochemistry, and Behavior·B CostallD M Tomkins
Jan 1, 1988·Annals of the New York Academy of Sciences·D R WeinbergerT N Chase
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jan 1, 1993·Drugs·V T Andriole
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Apr 1, 1997·Pharmacology, Biochemistry, and Behavior·S R HirschJ de Belleroche
Nov 20, 1997·Brain : a Journal of Neurology·C PantelisT W Robbins
Aug 7, 1998·Journal of Psychopharmacology·T J BlakeG P Reynolds
Jan 23, 1999·Biological Psychiatry·L D Selemon, P S Goldman-Rakic
Oct 12, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J S SprouseS H Zorn
Jul 27, 2000·Annals of the New York Academy of Sciences·F M Benes, S Berretta
Aug 16, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·W ZhangF P Bymaster
Jan 4, 2001·The American Journal of Psychiatry·R C SheltonH Y Meltzer
Feb 7, 2001·The American Journal of Psychiatry·P D Harvey, R S Keefe
Apr 21, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·O GefvertL Lindström
May 8, 2001·Trends in Pharmacological Sciences·V Di MatteoE Esposito
Oct 5, 2001·Trends in Pharmacological Sciences·P De Deurwaerdère, U Spampinato
Feb 19, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Junji IchikawaHerbert Y Meltzer
Apr 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sudabeh Shirazi-SouthallGeorge G Nomikos
Sep 13, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefania BonaccorsoJunji Ichikawa

❮ Previous
Next ❯

Citations

Oct 18, 2008·Psychopharmacology·David S TaitVerity J Brown
May 23, 2009·Psychopharmacology·Hugh M MarstonMohammed Shahid
Apr 23, 2013·European Journal of Pharmacology·Majid Jafari-SabetMohammad-Amin Khodadadnejad
Mar 15, 2012·Neuroreport·Mei HuangHerbert Y Meltzer
Oct 24, 2009·Neuropsychiatric Disease and Treatment·Delia Bishara, David Taylor
Aug 2, 2012·Expert Opinion on Pharmacotherapy·Frank I Tarazi, Stephen M Stahl
Oct 2, 2012·European Journal of Pharmacology·Rodolfo BongiovanniGeorge E Jaskiw
Apr 1, 2011·Revista de psiquiatrí́a y salud mental·Núria Cruz, Eduard Vieta
Jan 1, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ramez GhanbariPierre Blier
Nov 3, 2016·Acta Neuropsychiatrica·Masayo OhyamaTsukasa Koyama
Oct 20, 2009·The International Journal of Neuropsychopharmacology·Yong Kee ChoiFrank I Tarazi
Oct 9, 2013·The International Journal of Neuropsychopharmacology·Herbert Y MeltzerMasakuni Horiguchi
May 27, 2014·Frontiers in Cellular Neuroscience·Rasmus K ChristensenJean-François Perrier
Jul 28, 2016·Environmental Toxicology and Pharmacology·P RatajczakE Nowakowska
Aug 20, 2009·CNS Drugs·Juliane Weber, Paul L McCormack
Apr 19, 2017·CNS Neuroscience & Therapeutics·Sarah DelcourteNasser Haddjeri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.